Journal Article

Characteristics of Patients with Chronic Infection Due to Hepatitis C Virus of Mixed Subtype: Prevalence, Viral RNA Concentrations, and Response to Interferon Therapy

Hidenori Toyoda, Yoshihide Fukuda, Tetsuo Hayakawa, Tetsuo Takayama, Takashi Kumada, Satoshi Nakano, Junki Takamatsu and Hidehiko Saito

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 26, issue 2, pages 440-445
Published in print February 1998 | ISSN: 1058-4838
Published online February 1998 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/516332
Characteristics of Patients with Chronic Infection Due to Hepatitis C Virus of Mixed Subtype: Prevalence, Viral RNA Concentrations, and Response to Interferon Therapy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

We studied 349 patients with chronic infection due to hepatitis C virus (HCV), including 83 with coagulopathy, 122 with community-acquired infection, 20 with chronic posttransfusion hepatitis C, and 124 for whom the transmission mode was unknown. The prevalence of mixed-subtype HCV infection was investigated in each group of patients. The serum HCV RNA concentration and the response to interferon (IFN) therapy were evaluated. HCV infection with mixed subtypes was more frequent in patients who had been at high risk for exposure to HCV, such as those with coagulopathy or community-acquired infection. HCV RNA concentrations were lower in patients infected with mixed subtypes, except for those with subtypes 1a and 1b. Ten of 11 patients with mixed subtypes (not including those with 1a and 1b) achieved complete clearance of HCV RNA with IFN therapy.

Journal Article.  0 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.